SCHEMBL30504293

SCHEMBL30504293

CC(C)(C)OC(=O)NCc1cccc2cccc-2c1

nearest known ligand 0.56

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
▸ HDAC1 Q13547 1/20 0.56
▸ BRD4 O60885 3/20 0.55
▸ CREBBP Q92793 1/20 0.55
▸ CTSK P43235 2/20 0.55
▸ CTSB P07858 1/20 0.55
▸ CTSS P25774 1/20 0.55
▸ AOC3 Q16853 2/20 0.52
▸ GLS O94925 3/20 0.52
▸ KDM4A O75164 1/20 0.49
▸ PADI3 Q9ULW8 1/20 0.48
▸ PADI4 Q9UM07 1/20 0.48
▸ NAMPT P43490 2/20 0.46
▸ ERAP2 Q6P179 1/20 0.46
▸ ERAP1 Q9NZ08 1/20 0.46
▸ LNPEP Q9UIQ6 1/20 0.46
▸ CA12 O43570 1/20 0.46
▸ CA1 P00915 1/20 0.46
▸ CA7 P43166 1/20 0.46
▸ CA14 Q9ULX7 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18664426 0.97 HDAC1 (0.60) HDAC1BRD4CREBBPCTSKCTSB
SCHEMBL2568359 0.93 HDAC1 (0.56) HDAC1BRD4CREBBPCTSKCTSB
SCHEMBL16410240 0.93 BRD4 (0.53) HDAC1BRD4CREBBPCTSKCTSB
SCHEMBL6242494 0.92 HDAC1 (0.55) HDAC1BRD4CREBBPCTSKCTSB
SCHEMBL18664572 0.92 GRM2 (0.54) HDAC1BRD4CREBBPCTSKCTSB
SCHEMBL301717 0.92 PRMT6 (0.56) HDAC1BRD4CREBBPCTSKCTSB
SCHEMBL2572109 0.92 HDAC1 (0.52) HDAC1BRD4CREBBPCTSKCTSB
SCHEMBL5549803 0.91 HDAC1 (0.60) HDAC1BRD4CREBBPCTSKCTSB
SCHEMBL16410438 0.90 BRD4 (0.51) HDAC1BRD4CREBBPCTSKCTSB
SCHEMBL6243284 0.90 HDAC1 (0.51) HDAC1BRD4CREBBPCTSKCTSB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-116490507-A Heterocyclic condensation CDC7 kinase inhibitors for the treatment of cancer 薛定谔公司 2023-07-25 — — CN disclosed
Send feedback